10-K: Protagonist Therapeutics 2023 10-K Filing: Rusfertide and JNJ-2113 Lead Pipeline

Protagonist Therapeutics' 2023 10-K filing highlights the progress of their lead drug candidates, rusfertide for blood disorders and JNJ-2113 for inflammatory diseases, along with a new collaboration with Takeda.

Summary

• Protagonist Therapeutics is a biopharmaceutical company focused on peptide-based therapies.
• Their lead assets include rusfertide, an injectable hepcidin mimetic for polycythemia vera (PV), and JNJ-2113, an oral IL-23 receptor antagonist for inflammatory diseases.
• Rusfertide has shown positive Phase 2 results, including statistically significant improvements in hematocrit control and reduced need for phlebotomy.
• A global Phase 3 trial for rusfertide, VERIFY, is underway with expected enrollment completion by the end of the first quarter of 2024.
• The company entered a worldwide license and collaboration agreement with Takeda for rusfertide, expecting an upfront payment of $300 million and up to $330 million in milestones, plus tiered royalties.
• JNJ-2113 has completed a Phase 2b trial in psoriasis with positive topline results, showing significant improvements in PASI scores.
• JNJ has initiated multiple Phase 3 trials for JNJ-2113 in psoriasis and a Phase 2b trial in ulcerative colitis.
• Protagonist received a $50 million milestone payment from JNJ in late October 2023 and a $10 million milestone payment in December 2023.
• The company has a proprietary peptide technology platform that enables the development of novel, structurally constrained peptides.
• The company has a new oral Interleukin-17 (IL-17) peptide antagonist program targeting three IL-17 dimers (IL-17 AA, AF and FF) with a development candidate expected by the end of 2024.
• As of December 31, 2023, the company had $341.6 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in clinical trials and a major collaboration with Takeda. However, the company's history of losses and reliance on future funding introduce some uncertainty.

Positives

• The Takeda collaboration provides significant upfront capital and potential future revenue.
• JNJ-2113 is progressing through multiple Phase 3 trials, indicating strong potential for commercialization.
• The company's proprietary peptide technology platform is versatile and has led to multiple clinical-stage assets.
• The company has a strong cash position of $341.6 million as of December 31, 2023.
• The company has a new oral Interleukin-17 (IL-17) peptide antagonist program targeting three IL-17 dimers (IL-17 AA, AF and FF) with a development candidate expected by the end of 2024.

Negatives

• The company has incurred significant losses since its inception and expects to continue to incur losses.
• The company has no approved products and no historical commercial revenue.
• The company is heavily dependent on the success of its product candidates in clinical development.
• Clinical development is a lengthy and expensive process with an uncertain outcome.
• The company relies on third parties for manufacturing and clinical trials.
• The company may require additional funding, which may cause dilution to existing stockholders.

Risks

• Clinical trials may be delayed or fail to demonstrate safety and efficacy.
• Product candidates may cause undesirable side effects.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company may experience difficulties in managing the growth of its organization.
• The company is subject to risks associated with information technology systems or breaches of data security.
• The company's headquarters is located near known earthquake fault zones.
• The company may be involved in lawsuits to protect or enforce its intellectual property.
• The company's stock price has been and will likely continue to be volatile.
• The company may fail to obtain or protect intellectual property rights related to its product candidates and technologies.
• The company may face risks to its business arising from outbreaks of disease, epidemics and pandemics.
• Unstable market and economic conditions, including elevated and sustained inflation, may have serious adverse consequences on the company's business, financial condition and stock price.

Future Outlook

The company expects to continue to incur significant research and development expenses and other expenses related to its ongoing operations and product development. The company expects to receive an upfront payment of $300 million from Takeda and is eligible for up to $330 million in additional milestone payments, plus tiered royalties from 10% to 17% on ex-U.S. net sales. The company expects to be responsible for research and development through the completion of the Phase 3 VERIFY trial and U.S. regulatory approval.

Management Comments

• JNJ highlighted JNJ-2113 as a potential firstand best-in class targeted oral IL-23 peptide antagonist with potential across multiple indications, including plaque psoriasis, psoriatic arthritis and IBD, with potential peak year sales projection of $5.0 billion plus.

Industry Context

The document highlights the competitive landscape in the biotechnology and pharmaceutical industries, particularly in the areas of hematology, psoriasis, and inflammatory bowel disease. The company faces competition from established companies with approved injectable agents, as well as emerging companies developing oral therapies. The document also notes the increasing emphasis on cost-containment measures in healthcare, which could impact the pricing of the company's products.

Comparison to Industry Standards

• The document compares the company's product candidates to existing treatments and those in development.
• For PV, rusfertide is compared to ruxolitinib (Jakafi) and ropeginterferon alfa-2b (Besremi), highlighting rusfertide's potential as a non-cytoreductive therapy.
• In psoriasis and psoriatic arthritis, JNJ-2113 is compared to injectable agents like Cosentyx, Taltz, Tremfya, and Skyrizi, as well as oral agents like Otezla and Sotyktu.
• In IBD, the company's product candidates are compared to injectable anti-integrin and anti-IL-12/23 agents, as well as oral JAK inhibitors and S1P1 receptor modulators.
• The document notes that JNJ's IL-23 mAb drugs Stelara and Tremfya generated $14.0 billion in revenues in 2023, indicating the market potential for IL-23 pathway inhibitors.
• The document also mentions that Takeda reported 2022 sales of Entyvio of approximately $6.4 billion, and Johnson & Johnson global sales of Stelara were $10.9 billion in 2023, highlighting the market size for IBD therapies.

Stakeholder Impact

• Shareholders may benefit from the potential commercial success of the company's product candidates and the Takeda collaboration.
• Employees may benefit from the company's growth and development opportunities.
• Patients may benefit from the development of new therapies for polycythemia vera, psoriasis, and inflammatory bowel disease.
• The company's suppliers and contract manufacturers may benefit from increased business opportunities.

Next Steps

• Complete enrollment in the Phase 3 VERIFY trial for rusfertide by the end of the first quarter of 2024.
• Receive results of the two-year carcinogenicity study of rusfertide in rats by the end of 2024.
• Continue Phase 3 trials for JNJ-2113 in psoriasis and Phase 2b trial in ulcerative colitis.
• Nominate a development candidate for the oral Interleukin-17 (IL-17) peptide antagonist program by the end of 2024.

Key Dates

Keywords

rusfertide, JNJ-2113, polycythemia vera, inflammatory bowel disease, psoriasis, peptide therapeutics, clinical trials, Takeda, IL-23 receptor antagonist, hepcidin mimetic